keyword
MENU ▼
Read by QxMD icon Read
search

Pet psma

keyword
https://www.readbyqxmd.com/read/29905907/-68-ga-psma-11-pet-ct-in-prostate-cancer-patients-with-biochemical-recurrence-after-radical-prostatectomy-and-psa-0-5-ng-ml-efficacy-and-impact-on-treatment-strategy
#1
Andrea Farolfi, Francesco Ceci, Paolo Castellucci, Tiziano Graziani, Giambattista Siepe, Alessandro Lambertini, Riccardo Schiavina, Filippo Lodi, Alessio G Morganti, Stefano Fanti
PURPOSE: The primary aim of this retrospective, single-centre analysis was to assess the performance of 68 Ga-PSMA-11 PET/CT in prostate cancer (PCa) patients in early PSA failure after radical prostatectomy (RP). The secondary aim was to assess the potential impact of 68 Ga-PSMA-11 PET/CT on treatment strategy. METHODS: 68 Ga-PSMA-11 PET/CT is performed in our institution within an investigational new drug (IND) trial in PCa patients with biochemical recurrence (BCR)...
June 15, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29894339/prostate-specific-membrane-antigen-expression-in-distal-radius-fracture
#2
Sebastian Hoberück, Enrico Michler, Daniel Kaiser, Anne Röhnert, Klaus Zöphel, Jörg Kotzerke
A 79-year old man with prostate cancer under active surveillance for 5 years was referred for a PSMA-PET/MRI for re-evaluation because of a rising prostate-specific antigen value. PET/MRI revealed a ribbonlike tracer accumulation in a healing fracture of the distal radius. This case illustrates that PSMA expression may occur in healing bone fractures in the distal radius. It can be assumed that benign causes of tracer accumulations in the upper extremities are missed in PET/CT due to elevated position of the arms during image acquisition...
June 12, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29894335/evidence-of-prostate-specific-membrane-antigen-expression-in-metastatic-differentiated-thyroid-cancer-using-68ga-psma-hbed-cc-pet-ct
#3
Priyanka Verma, Gaurav Malhotra, Ritesh Agrawal, Sunita Sonavane, Vilas Meshram, Ramesh V Asopa
PURPOSE OF THE REPORT: Prostate-specific membrane antigen (PSMA) overexpression is not restricted to prostate cancer, but it has also been demonstrated in gliomas, lung cancer, and in tumor neovasculature. Systematic studies exploring PSMA uptake in thyroid tumors are lacking. The aim of this pilot study was to assess PSMA expression in patients with metastatic differentiated thyroid cancer (mDTC). MATERIALS AND METHODS: Ten patients of mDTC harboring 32 lesions (5 men; age range, 38-65 years; mean age, 50 years) underwent prospective evaluation with radioiodine (I), F-FDG PET, and Ga-PSMA-HBED-CC PET scans as per the institution protocol...
June 12, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29876619/prospective-comparison-of-68-ga-psma-pet-ct-18-f-sodium-fluoride-pet-ct-and-diffusion-weighted-mri-at-for-the-detection-of-bone-metastases-in-biochemically-recurrent-prostate-cancer
#4
Helle D Zacho, Julie B Nielsen, Ali Afshar-Oromieh, Uwe Haberkorn, Nandita deSouza, Katja De Paepe, Katja Dettmann, Niels C Langkilde, Christian Haarmark, Rune V Fisker, Dennis T Arp, Jesper Carl, Jørgen B Jensen, Lars J Petersen
PURPOSE: To prospectively compare diagnostic accuracies for detection of bone metastases by 68 Ga-PSMA PET/CT, 18 F-NaF PET/CT and diffusion-weighted MRI (DW600 -MRI) in prostate cancer (PCa) patients with biochemical recurrence (BCR). METHODS: Sixty-eight PCa patients with BCR participated in this prospective study. The patients underwent 68 Ga-PSMA PET/CT, a 18 F-NaF PET/CT and a DW600 -MRI (performed in accordance with European Society of Urogenital Radiology guidelines, with b values of 0 and 600 s/mm2 )...
June 6, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29873506/clinical-evaluation-of-68-ga-psma-ii-and-68-ga-rm2-pet-images-reconstructed-with-an-improved-scatter-correction-algorithm
#5
Kristen A Wangerin, Lucia Baratto, Mohammad Mehdi Khalighi, Thomas A Hope, Praveen K Gulaka, Timothy W Deller, Andrei H Iagaru
OBJECTIVE: Gallium-68-labeled radiopharmaceuticals pose a challenge for scatter estimation because their targeted nature can produce high contrast in these regions of the kidneys and bladder. Even small errors in the scatter estimate can result in washout artifacts. Administration of diuretics can reduce these artifacts, but they may result in adverse events. Here, we investigated the ability of algorithmic modifications to mitigate washout artifacts and eliminate the need for diuretics or other interventions...
June 6, 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29871008/-psma-pet-ct-has-to-be-performed-in-every-patient-with-biochemical-recurrence-following-radical-prostatectomy-for-early-tumor-detection
#6
Jörg Kotzerke, Dirk Böhmer, Thorsten Schlomm, Thomas Maurer, Ambros J Beer, Heinz Schmidberger
The debate refers the known evidence for PSMA-PET/CT in biochemical recurrence of prostate cancer and consider carefully interdisciplinary in which situation which patient needs imaging to choose the adequate therapeutic option. General aspects for the care of cancer patients are taken into consideration.
June 2018: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/29869483/pet-imaging-in-adaptive-radiotherapy-of-prostate-tumors
#7
Bettina Beuthien-Baumann, Stefan A Koerber
The integration of data from positron-emission-tomography, combined with computed tomography as PET/CT or combined with magnet resonance imaging as PET/MRI, into radiation treatment planning of prostate cancer is gaining higher impact with the development of more sensitive and specific radioligands. The classic PET-tracer for prostate cancer imaging are [11C]choline and [11C]acetate, which are currently outperformed by ligands binding to the prostate-specific- membrane-antigen (PSMA). [68Ga]PSMA-11, which is the most frequently applied tracer, has shown to detect lymph node metastases, local recurrences, distant metastases and intraprostatic foci with high sensitivity, even at relatively low PSA levels...
June 4, 2018: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29865797/radioligand-therapy-of-prostate-cancer-with-a-long-lasting-psma-targeting-agent-90y-dota-eb-mcg
#8
Zhantong Wang, Orit Jacobson, Rui Tian, Ronnie C Mease, Dale Kiesewetter, Gang Niu, Martin G Pomper, Xiaoyuan Chen
Several radioligands targeting prostate-specific membrane antigen (PSMA) have been clinically introduced as a new class of radiotheranostics for the treatment of prostate cancer. Among them, (((R)-1-carboxy-2-mcercaptoethyl)carbamoyl)-L-glutamic acid (MCG) has been successfully labeled with radioisotopes for prostate cancer imaging. The aim of this study is to conjugate MCG with an albumin binding moiety to further improve the in vivo pharmacokinetics. METHODS: MCG was conjugated with an Evans blue (EB) derivative for albumin binding and a DOTA chelator...
June 4, 2018: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/29858591/-68-ga-psma-pet-ct-vs-mpmri-for-locoregional-prostate-cancer-staging-correlation-with-final-histopathology
#9
I Berger, C Annabattula, J Lewis, D V Shetty, J Kam, F Maclean, M Arianayagam, B Canagasingham, R Ferguson, M Khadra, R Ko, M Winter, H Loh, C Varol
BACKGROUND: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) can be used to locate lesions based on PSMA avidity, however guidelines on its use are limited by its infancy. We aimed to compare multiparametric magnetic resonance imaging (mpMRI) and PSMA PET/CT to prostatectomy histopathology. METHODS: We conducted a chart review from February 2015 to January 2017 of 50 male patients staged for prostate cancer using PSMA PET/CT and mpMRI who then underwent radical prostatectomy...
June 1, 2018: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/29847319/68ga-psma-pet-mr-positive-histopathology-proven-prostate-cancer-in-a-patient-with-negative-multiparametric-prostate-mri
#10
Urs J Muehlematter, Niels J Rupp, Julian Mueller, Daniel Eberli, Irene A Burger
Multiparametric MRI incorporating T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced sequences is currently used for detection and localization of clinically important prostate cancer (PCa). The Ga-labeled PET tracer targeting the prostate-specific membrane antigen (PSMA, Ga-PSMA-11) is a promising diagnostic approach for staging and restating PCa. Recent studies suggest that Ga-PSMA could also be used for primary PCa detection and localization. We report a case of a Ga-PSMA PET/MR-positive lesion of the peripheral zone in a 73-year-old man with a negative preceding multiparametric MRI...
May 25, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29846803/quantitative-characterisation-of-clinically-significant-intra-prostatic-cancer-by-prostate-specific-membrane-antigen-psma-expression-and-cell-density-on-psma-11
#11
Liran Domachevsky, Natalia Goldberg, Hanna Bernstine, Meital Nidam, David Groshar
OBJECTIVES: To quantitatively characterize clinically significant intra-prostatic cancer (IPC) by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11 positron emission tomography/magnetic resonance (PET/MR). METHODS: Retrospective study approved by the institutional review board with informed written consent obtained. Patients with a solitary, biopsy-proven prostate cancer, Gleason score (GS) ≥7, presenting for initial evaluation by PET/computerised tomography (PET/CT), underwent early prostate PET/MR immediately after PSMA-11 tracer injection...
May 30, 2018: European Radiology
https://www.readbyqxmd.com/read/29794224/one-stop-shop-whole-body-68-ga-psma-11-pet-mri-compared-to-clinical-nomograms-for-preoperative-t-and-n-staging-of-high-risk-prostate-cancer
#12
Mark Thalgott, Charlotte Düwel, Isabel Rauscher, Matthias M Heck, Bernhard Haller, Andrei Gafita, Jürgen E Gschwend, Markus Schwaiger, Tobias Maurer, Matthias Eiber
Our aim was to assess the diagnostic potential of one-stop shop Prostate-specific membrane antigen-ligand Positron Emission Tomography/Magnetic Resonance Imaging (68 Ga-PSMA-11 PET/MRI) compared to preoperative staging nomograms in patients with high-risk prostate cancer (PC). Methods: A total of 102 patients underwent 68 Ga-PSMA-11 PET/MRI before intended radical prostatectomy (RP) with lymph node dissection. Preoperative variables determined the probabilities for lymph node metastases (LNM), extracapsular extension (ECE) and seminal vesical involvement (SVI) using the Memorial Sloan-Kettering Cancer Center (MSKCC) nomogram and Partin tables...
May 24, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29789766/salvage-high-dose-rate-brachytherapy-for-prostate-cancer-persistence-after-brachytherapy-repeated-use-of-a-polyethylene-glycol-hydrogel-spacer
#13
Rodrigo Hepp, Thilo Eggert, Georg Schabl, Lars Herberholz, Tim Petry, Razvan Galalae
Purpose: The aim of this study is to determine if a repeated hydrogel injection in a previously irradiated patient prior to salvage high-dose-rate brachytherapy (HDR-BT) is feasible. Material and methods: A 61-year-old man with an organ confined (cT1c cN0 cM0, Gleason score 3 + 3 = 6, initial prostate-specific antigen [PSA] 7.9 ng/ml) prostate cancer was previously treated with HDR-BT (3 fractions of 11.5 Gy every 2nd week) after hydrogel injection to reduce the rectal dose...
April 2018: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/29786490/gallium-68-psma-11-pet-mr-imaging-in-patients-with-intermediate-or-high-risk-prostate-cancer
#14
Sonya Youngju Park, Claudia Zacharias, Caitlyn Harrison, Richard E Fan, Christian Kunder, Negin Hatami, Frederik Giesel, Pejman Ghanouni, Bruce Daniel, Andreas M Loening, Geoffrey A Sonn, Andrei Iagaru
Purpose To report the results of dual-time-point gallium 68 (68 Ga) prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/magnetic resonance (MR) imaging prior to prostatectomy in patients with intermediate- or high-risk cancer. Materials and Methods Thirty-three men who underwent conventional imaging as clinically indicated and who were scheduled for radical prostatectomy with pelvic lymph node dissection were recruited for this study. A mean dose of 4.1 mCi ± 0.7 (151.7 MBq ± 25...
May 16, 2018: Radiology
https://www.readbyqxmd.com/read/29782606/-68-ga-psma-and-11-c-choline-comparison-using-a-tri-modality-pet-ct-mri-3-0-t-system-with-a-dedicated-shuttle
#15
Omar Alonso, Gerardo Dos Santos, Margarita García Fontes, Henia Balter, Henry Engler
Background: The aim of this study was to prospectively compare the detection rate of 68 Ga-PSMA versus 11 C-Choline in men with prostate cancer with biochemical recurrence and to demonstrate the added value of a tri-modality PET/CT-MRI system. Methods: We analysed 36 patients who underwent both 11 C-Choline PET/CT and 68 Ga-PSMA PET/CT scanning within a time window of 1-2 weeks. Additionally, for the 68 Ga-PSMA scan, we used a PET/CT-MRI (3.0 T) system with a dedicated shuttle, acquiring MRI images of the pelvis...
2018: European journal of hybrid imaging
https://www.readbyqxmd.com/read/29777523/application-of-cu-64-nodaga-psma-pet-in-prostate-cancer
#16
Sabina Sevcenco, Hans Christoph Klingler, Klaus Eredics, Alexander Friedl, Jenifer Schneeweiss, Peter Knoll, Thomas Kunit, Lukas Lusuardi, Siroos Mirzaei
INTRODUCTION: The high diagnostic potential of 64 Cu-PSMA PET-CT imaging was clinically investigated in prostate cancer patients with recurrent disease and in the primary staging of selected patients with advanced local disease. The aim of our study is to assess the uptake behavior in the clinical setting of 64Copper Prostate-Specific Membrane Antigen (64 Cu PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) in prostate cancer. METHODS: A retrospective study was performed in 23 patients with intermediate, high risk and progressive disease at primary staging of prostate cancer...
May 17, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29769114/-68-ga-psma-pet-ct-for-the-evaluation-of-pulmonary-metastases-and-opacities-in-patients-with-prostate-cancer
#17
Jonathan Damjanovic, Jan-Carlo Janssen, Christian Furth, Gerd Diederichs, Thula Walter, Holger Amthauer, Marcus R Makowski
BACKGROUND: The purpose of this study was to investigate the imaging properties of pulmonary metastases and benign opacities in 68 Ga-PSMA positron emission tomography (PET) in patients with prostate cancer (PC). METHODS: 68 Ga-PSMA-PET/CT scans of 739 PC patients available in our database were evaluated retrospectively for lung metastases and non-solid focal pulmonary opacities. Maximum standardized uptake values (SUVmax ) were assessed by two- and three-dimensional regions of interest (2D/3D ROI)...
May 16, 2018: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/29766246/comparison-of-68-ga-ga-psma-11-pet-ct-with-18-f-naf-pet-ct-in-the-evaluation-of-bone-metastases-in-metastatic-prostate-cancer-patients-prior-to-radionuclide-therapy
#18
Christian Uprimny, Anna Svirydenka, Josef Fritz, Alexander Stephan Kroiss, Bernhard Nilica, Clemens Decristoforo, Roland Haubner, Elisabeth von Guggenberg, Sabine Buxbaum, Wolfgang Horninger, Irene Johanna Virgolini
AIM: The purpose of this study was to investigate the diagnostic performance of 68 Ga-PSMA-11 PET/CT in the evaluation of bone metastases in metastatic prostate cancer (PC) patients scheduled for radionuclide therapy in comparison to [18 F]sodium fluoride (18 F-NaF) PET/CT. METHODS: Sixteen metastatic PC patients with known skeletal metastases, who underwent both 68 Ga-PSMA-11 PET/CT and 18 F-NaF PET/CT for assessment of metastatic burden prior to radionuclide therapy, were analysed retrospectively...
May 16, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29761524/the-24th-annual-prostate-cancer-foundation-scientific-retreat-report
#19
REVIEW
Andrea K Miyahira, Howard R Soule
INTRODUCTION: The 24th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held from October 5-7, 2017, at the Omni Shoreham Hotel in Washington, DC. METHODS: The PCF Scientific Retreat is a scientific conference that specifically focuses on cutting edge research deemed to have significant promise for accelerating advances in prostate cancer biology and treatment. RESULTS: Themes highlighted at this year's meeting included: (i) new understandings in prostate cancer biology and disease progression; (ii) new mechanisms and treatment targets in advanced prostate cancer; (iii) advances in precision medicine genomics, germline genetics, and selection of targeted therapies; (iv) PSMA-targeted agents for PET imaging and radionuclide therapy; (v) approaches for improving the efficacy of immunotherapy in prostate cancer; (vi) applications of 3D Genomics in prostate cancer research; and (vii) potential applications of artificial intelligence in prostate cancer...
May 15, 2018: Prostate
https://www.readbyqxmd.com/read/29752513/oligorecurrent-prostate-cancer-limited-to-lymph-nodes-getting-our-ducks-in-a-row
#20
Andrei Fodor, Andrea Lancia, Francesco Ceci, Maria Picchio, Morten Hoyer, Barbara Alicja Jereczek-Fossa, Piet Ost, Paolo Castellucci, Elena Incerti, Nadia Di Muzio, Gianluca Ingrosso
PURPOSE: Oligorecurrent prostate cancer with exclusive nodal involvement represents a common state of disease, amenable to local therapy. New radio-labeled tracers have enriched the possibility of cancer detection and treatment. In this review, we aim to illustrate the main nuclear medicine diagnostic options and the role of radiotherapy in this setting of patients. METHODS: We performed a PubMed search referring to the PRISMA guidelines to analyze the performance of PSMA- and choline-PET in detecting oligorecurrence limited to lymph nodes, and to review the main studies supporting either ablative stereotactic body radiotherapy or regional lymph node irradiation in this clinical setting...
May 11, 2018: World Journal of Urology
keyword
keyword
110902
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"